logo
Plus   Neg
Share
Email

Advanced Semiconductor Engineering March Revenue Falls - Update

Advanced Semiconductor Engineering, Inc. (ASX), or ASE, on Monday reported a fall in revenue for March from last year, while revenue improved sequentially from the prior month.

The Kaohsiung, Taiwan-based company provides semiconductor packaging and testing services in the U.S., Taiwan, Asia and Europe.

Net revenues for March slipped 7 percent from last year to T$15.365 billion ($521 million) from T$16.527 billion in the prior year. Sequentially, revenues grew 8.4 percent.

For the first quarter, revenue dropped 6.3 percent to T$43.101 billion and declined 7.1 percent from the prior quarter.

ASE noted that from February 1, 2010, Universal Scientific Industrial Co., Ltd.'s consolidated revenues were consolidated into its consolidated revenues.

Net revenues for the ATM assembly test and material business, excluding USI, for March slipped 5.4 percent from last year to T$10.405 billion. For the quarter, revenue dropped 5.3 percent to T$29.24 billion.

ASX closed on Thursday at $5.00, up $0.01, on a volume of 1.42 million shares.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT